Table 61:
Scenario Analysis Results, nVNS for Prevention, Migraine
| Scenario | Budget impact, $ milliona | |||||
|---|---|---|---|---|---|---|
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Totalb | |
| Reference case | 17.76 | 36.27 | 55.32 | 74.74 | 94.70 | 278.77 |
| 1: nVNS provided free for the first 93 days | 11.55 | 23.59 | 35.98 | 48.61 | 61.59 | 181.32 |
| 2: Annual uptake of 2% per year, up to 10% in year 5 | 35.51 | 72.54 | 110.64 | 149.47 | 189.38 | 557.54 |
| 3: Annual uptake of 20% per year, up to 100% in year 5 | 444.49 | 907.95 | 1,384.93 | 1,870.92 | 2,370.45 | 6,978.74 |
| 4a: Cost of the nVNS device decreased by 25% | 13.28 | 27.12 | 41.37 | 55.89 | 70.82 | 208.49 |
| 4b: Cost of the nVNS device increased by 25% | 22.22 | 45.40 | 69.25 | 93.55 | 118.52 | 348.94 |
Abbreviation: nVNS, noninvasive vagus nerve stimulation.
a
In 2024 Canadian dollars.
b
Results may appear inexact due to rounding.